Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2019 /
Biomarkers of systemic inflammation linked to reduced clinical activity of atezolizumab monotherapy in metastatic TNBC

29th Mar - 3rd Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.04.19
Views: 939

Luciana Molinero - Genentech, San Francisco, USA

Luciana Molinero speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about a study looking at the biomarkers of systemic inflammation associated to reduced clinical activity of atezolizumab monotherapy in patients with metastatic triple negative breast cancer (TNBC).

She explains that it was found that patients that have activation of the IL-6 and CRP tend to have reduced clinical outcome.

This is in comparison to combination treatment where response rates increased dramatically, showing that the IL-6/CRP inflammatory axis is a factor leading to poorer outcomes.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation